About Atara Biotherapeutics, Inc.
https://www.atarabio.comAtara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.
CEO
Anhco Nguyen
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-06-20 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
KPCB XV ASSOCIATES, LLC
Shares:1.88M
Value:$8.67M
BLACKROCK FUND ADVISORS
Shares:1.11M
Value:$5.14M
ANTIPODEAN ADVISORS LLC
Shares:1M
Value:$4.62M
Summary
Showing Top 3 of 61
About Atara Biotherapeutics, Inc.
https://www.atarabio.comAtara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.45M ▼ | $6.88M ▼ | $-4.3M ▼ | -124.62% ▼ | $-0.32 ▼ | $-3.33M ▼ |
| Q2-2025 | $17.57M ▼ | $13.82M ▼ | $2.39M ▼ | 13.58% ▼ | $0.2 ▼ | $3.6M ▼ |
| Q1-2025 | $98.15M ▲ | $38.91M ▲ | $38.01M ▲ | 38.73% ▲ | $3.53 ▲ | $40.82M ▲ |
| Q4-2024 | $32.75M ▼ | $38.16M ▼ | $-12.69M ▲ | -38.75% ▲ | $-1.19 ▲ | $-10.6M ▲ |
| Q3-2024 | $40.19M | $54.34M | $-21.91M | -54.51% | $-2.93 | $-19.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $13.71M ▼ | $30.17M ▼ | $66.8M ▼ | $-36.63M ▼ |
| Q2-2025 | $22.32M ▲ | $36.9M ▼ | $71.94M ▼ | $-35.04M ▲ |
| Q1-2025 | $13.84M ▼ | $62.04M ▼ | $117.11M ▼ | $-55.07M ▲ |
| Q4-2024 | $42.5M ▼ | $109.1M ▼ | $206.38M ▼ | $-97.28M ▼ |
| Q3-2024 | $67.19M | $142.71M | $233.25M | $-90.54M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.3M ▼ | $-9.79M ▼ | $-2.42M ▲ | $1.05M ▼ | $-11.16M ▼ | $-9.79M ▼ |
| Q2-2025 | $2.39M ▼ | $-7.32M ▲ | $-5.07M ▼ | $15.3M ▲ | $2.92M ▲ | $-7.32M ▲ |
| Q1-2025 | $38.01M ▲ | $-28.14M ▼ | $17.2M ▲ | $-250K ▲ | $-11.19M ▲ | $-28.14M ▼ |
| Q4-2024 | $-12.69M ▲ | $-24.47M ▼ | $3.38M ▲ | $-328K ▼ | $-21.42M ▼ | $-24.56M ▼ |
| Q3-2024 | $-21.91M | $-3.99M | $-16.66M | $35.79M | $15.14M | $-3.99M |
CEO
Anhco Nguyen
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-06-20 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
KPCB XV ASSOCIATES, LLC
Shares:1.88M
Value:$8.67M
BLACKROCK FUND ADVISORS
Shares:1.11M
Value:$5.14M
ANTIPODEAN ADVISORS LLC
Shares:1M
Value:$4.62M
Summary
Showing Top 3 of 61